Loading
companiesCompany
Freenome
Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.
Overview
FDA approved SimpleScreen CRC on 24 July 2026 for average-risk adults 45+ based on PREEMPT CRC (>48,000 participants; ~80% CRC sensitivity, ~90% specificity). Freenome listed via a $330M SPAC merger (2025-26); Abbott holds US commercial rights and paid a $100M approval milestone; launch expected autumn 2026.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#186of 1244 companies, score 31
- approved products +12
- modalities +2
- regions +1
- 24-month regulatory events +2
- registry trials +14
2 approved, 0 in phase 3, 0 earlier, 0 targets, 52 registry studies. Formula on the scorecards page.
Type
Diagnostics · FRNM
Stage
Public
Website
ApprovedBlood-based colorectal cancer screening test
The first FDA-approved blood test for colorectal cancer screening (2024), now optionally reporting other cancers too.
ApprovedBlood-based colorectal cancer screening test (cfDNA methylation and protein)
SimpleScreen CRC · SimpleScreen
The second FDA-approved blood test for bowel cancer screening, from Freenome, sold by Abbott from late 2026.
Similar pages
- TreatmentCancerguard
Shares Shield, Multi-cancer early detection (MCED), DNA methylation profiling, Liquid biopsy (ctDNA).
- IdeaMandatory interval-cancer audit for every blood-based screening test
Shares Shield, Multi-cancer early detection (MCED), The hardest cancers are found late, Liquid biopsy (ctDNA).
- TreatmentCologuard Plus
Shares SimpleScreen CRC, Shield, DNA methylation profiling, Colorectal cancer.
- TechnologyCell-free DNA methylation tests
Shares Multi-cancer early detection (MCED), DNA methylation profiling, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
- CompanyExact Sciences (Abbott)
Shares Abbott Laboratories, Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, The hardest cancers are found late.
- CompanyClearNote Health
Shares Multi-cancer early detection (MCED), DNA methylation profiling, Liquid biopsy (ctDNA).
- TrialECLIPSE (Shield blood test)
Shares Shield, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Colorectal cancer.
- CompanyGuardant Health
Shares Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy, Shield, Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
cancers
fronts
technologies
drugs
ApprovedBlood-based colorectal cancer screening test
ApprovedBlood-based colorectal cancer screening test (cfDNA methylation and protein)
SimpleScreen CRC · SimpleScreen